NextGen Biomed 2025

12 - 14 March 2025 | London, UK

From groundbreaking discoveries to real-world applications: Bringing the next generation of biomedicines from concept to market

Proteins, Antibodies & ADCs
Peptides
Oligonucleotides
Sustainability in Tides & Biologics
Immunotherapy & Immuno-oncology
Vaccines
Overview Proteins, Antibodies & ADCs Peptides Oligonucleotides Sustainability in Tides & Biologics Immunotherapy & Immuno-oncology Vaccines

Explore NextGen Biomed 2025: Unlocking Future Insights in Biomedicine Research & Development

Join leaders, experts and researchers at NextGen Biomed 2025, connecting pharmaceutical & biotech representatives as well as academia for high-level discussions on the latest innovations in biomedicine discovery & development. Bringing together our established Biologics & Tides and Immuno events, NextGen Biomed 2025 features 6 dedicated programmes: Proteins & Antibodies, Peptides, Oligonucleotides, Sustainability in Tides & Biologics, Immunotherapy & Immuno-oncology, and Vaccines.

NextGen Biomed 2025 is supported by our Scientific Programme Partner The Antibody Society

Proteins & Antibodies

Join leading scientific experts within Proteins & Antibodies, addressing critical strategies and the latest technological advancements in antibody engineering, bioanalytical techniques as well as the latest case studies in the development of next-generation biotherapeutics.

  • New to 2025! Gain invaluable insights into novel strategies for cell line development & optimisation. Presentations will cover transposase mediated cell line generation, cell culturing techniques and advancing viral vector production through cell line development and engineering
  • Gain a comprehensive understanding of downstream development for antibodies and Fc containing molecules. From Intensifying processes to improve productivity and reduce processing time, through to addressing protein aggregation challenges and single use technologies
  • Discuss the latest novel tools & technologies for the display of biologics. Key opinion leaders will be presenting on addressing difficult targets with display technologies as well as developing novel in vitro display technologies for antibody discovery & engineering
  • Take a deep dive into novel clinical development strategies through engaging presentations on selecting patient population, ADC clinical development, designing clinical trials to get the best proof of concept & insights into non-oncology indications
  • Tap into the latest in ADC optimisation to enhance therapeutic potential through exciting sessions on linker / payload technologies, conjugation strategies and more

Agenda at a Glance


Day One

  • Track 1: Novel Tools & Technologies for the Display of Proteins & Antibodies
  • Track 2: ADC Design, Validation & Optimization to Enhance Their Therapeutic Potential
  • Track 3: Analytical Development: Stability & In-Depth Characterisation Methods for Proteins & Antibodies
  • Track 4: Novel Strategies for Cell Line Development & Expression Optimisation

Day Two

  • Track 1: Antibody Discovery & Engineering
  • Track 2: New Formats: Cytokines & Immunocytokines
  • Track 3: Emerging Analytical Techniques, Developability & Quality Control Systems
  • Track 4: Downstream Development for Antibodies and Fc Containing Molecules

Day Three

  • Track 1: AI/ML-Guided Protein & Antibody Engineering
  • Track 2: NextGen Multi-Specifics, Cell Engagers & Other New Modalities
  • Track 3: Novel Strategies for Clinical Development
  • Track 4: Novel Protein Process Development: Protein Purification & Recombinant Protein Production

Peptides

Peptides will bring together key experts in peptide chemistry and therapeutic development. With the latest technological advancements pushing the industry forward, join us in London to network, debate and discuss the pressing challenges & future opportunities.

  • New to 2025! Discuss the latest innovations in peptide therapeutics analysis. Key opinion leaders will cover the latest advancements in mass spec methods such as de novo sequencing & quantitative proteomics; AI/ML for therapeutics analysis and peptide sequencing
  • Stay at the forefront of peptide therapeutics research & development with hearing about novel targeted delivery methods, advances in peptide design and characterisation updates
  • Discover the latest innovations in peptide chemistry including advanced computational methods and the implementation of AI/ML technologies

Agenda at a Glance


Day One: Peptide Discovery

Day Two: Peptide Chemistry

Day Three: Peptide Therapeutics & Development

Oligonucleotides

Join key opinion leaders, bringing about a new era of innovation in this field. Presentations will be covering computational approaches, methods & tools to oligonucleotide CMC as well as analytical control strategies for oligos.

  • New to 2025! Take a deep dive into oligo therapeutics analysis – from cell-based assay development through to improved computational methods, strategies & approaches including gene editors, CRISPR/CAS systems and guide RNA design
  • Discuss the latest therapeutic development success stories with thought-leaders presenting on immunogenicity considerations, progress to clinical trials and RNA targeting
  • Stay up-to-date with current advances in oligonucleotide delivery with presentations on nanoparticle technologies and conjugation strategies

Agenda at a Glance


Day One: Oligo Discovery

Day Two: Oligo Chemistry & CMC

Day Three: Oligonucleotide Therapeutic Development & Optimisation

Sustainability in Tides & Biologics

Sustainability in Tides & Biologics addresses an important and expanding area, providing insights into driving sustainable innovation across biologics research & development; from sustainable synthesis approaches through to green manufacturing and sustainable supply chain processes.

  • New to 2025! Immerse yourself in innovations pertaining to peptide & oligo green chemistry, manufacturing and sustainable supply chain development. Presentations will delve into sustainable engineering practices, advanced solvent recovery systems and ensuring supply chain continuity
  • Express your thoughts on the future of solvent recovery systems and implementation of new sustainable manufacturing technologies, as well as taking a look at green manufacturing regulations
  • Explore the latest methodology in sustainable drug formulations including the usage of green and renewable APIs

Agenda at a Glance


Day One: Peptides & Oligo Green Chemistry

Day Two: Green Innovations in Peptide & Oligo Manufacturing

Day Three: Towards Sustainable Supply Chain Development & Commercialisation for Biologics

Immunotherapy & Immuno-oncology

A carefully curated event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of novel  immunotherapies; advances in cellular, antibody and combination therapy development as well as personalised cancer therapy treatments.

 

  • New to 2025! Gain invaluable insights into advancing immunotherapy strategies to treat cancer & autoimmune diseases. Presentations will cover the current immunotherapy strategies, latest innovations in cancer immunotherapy, cytokine therapies & anti T cell therapies 
  • New to 2025! Discover the promise of the microbiome & the gut immune axis. Take a deep dive into understanding the relationship between the microbiome and cancer to transform immune-modulating therapies; the role of microbiota in metabolisms & immunity as well as novel technologies for microbiome analysis 
  • New to 2025! Hear key opinion leaders tapping into personalized cancer therapies. Hear about advancements in cancer vaccine development, vaccines for non-infectious diseases and neoantigen identification strategies 
  • Explore predictive models & tools for preclinical evaluation and translational development. Thought-leaders will be discussing humanized and 3D models, maximizing translatability through effective in vitro and in vivo models and the role of the tumor microenvironment in ensuring clinical success

Agenda at a Glance


Day One:

  • Track 7: Immunotherapy Strategies
  • Track 8: Discovery & Development: Cell & Gene and Combination Therapies
  • Track 9: Biomarkers, ctDNA, Precision Medicine & Multi-Omics In Immuno-Oncology

Day Two

  • Track 7: New Clinical Development for Immunotherapies
  • Track 8: Predictive Models & Tools for Preclinical Evaluation and Translational Development
  • Track 9: Personalised Cancer Therapies

Day Three

  • Track 7: Microbiome & the Gut-Immune Axis
  • Track 8: Discovery & Development: Antibody Therapies
  • Track 9: Novel Targets in Immuno-oncology: Identification, Validation & Exploration

Vaccines

Delve into the latest in immunotherapy and vaccine discovery and development: from advanced nucleotide based platforms for infectious diseases, to antigen development, to immunotherapy strategies for cancer and autoimmune disease, through to novel delivery systems & adjuvant production.

  • New to 2025! Gain invaluable insights into novel nucleotides, biologics & other vaccine platforms. Presentations will cover modern vaccine technologies such as mRNA and new DNA vaccines, advanced antigen development and live-attenuated and inactivated vaccine platforms  
  • New to 2025! Discover the latest innovations in vaccine analytical testing & stability. Take a deep dive into gene expression testing, lab automation for mRNA vaccines screening and pioneering computational approaches, methods & tools such as codon optimization design and UTR optimization  
  • New to 2025! Hear key opinion leaders discussing preclinical innovation & clinical development got mRNA vaccines. Learn about advancements in biomarker studies from mRNA vaccines evaluation, new cell-specific targeting approaches and pandemic preparedness  
  • Devised with the help of our esteemed advisory board. Presentations will also look at lessons learnt from the SARS-CoV2 mRNA vaccine campaigns, vaccine stability testing techniques and immune-reactogenicity of mRNA vaccines

Agenda at a Glance


  • Day One: Nucleotides, Biologics & Other Vaccine Platforms for Infectious Diseases & Antigen Development
  • Day Two: Vaccine Analytical Testing & Stability
  • Day Three: Preclinical Innovation & Clinical Development for mRNA Vaccines
ACROBiosystems Logo

Biologics 2024 has been one of the best events I have attended so far in my career.

 

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Genscript Logo

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

 

Advanced Therapies Specialist Team Leader,
Genscript

Bioassay a Reaction Biology Company

 

Impressed by the effort to bring people together.

 

Business Development Director,

Bioassay

ImmunoPrecise

 

Nice set-up, with good support for exhibitors

 

Director of Client Relations,

ImmunoPrecise

What to Expect

1000

leading pharma, biotech, healthcare & academic delegates

50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including speed networking & refreshments
700
pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership-1
What to Expect Global Technological Showcase-1
What to Expect Networking Emphasis-1
What to Expect Innovative Poster Displays-1

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Experience over 200 dynamic interactive discussions, C-level debates, collaborative roundtables, and thought-provoking presentations & innovation showcases curated with insights from top industry leaders and experts to benchmark your research & development pipeline
  • Global Technological Showcase

    An international & dynamic exhibition showcasing cutting-edge technologies and services from premier providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, personalised 1-2-1 meetings, a vibrant drinks reception, and informal gatherings to foster meaningful connections.
  • Innovative Poster Displays & Awards Ceremony

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and start-up companies.

Key Themes for NextGen Biomed 2025

The 2025 programmes will explore the entire value chain involved in bringing next-generation biomedicines to market. The Proteins & Antibodies programme will offer an in-depth analysis of the latest advancements, covering everything from antibody discovery to analytical and clinical development, along with new formats and next-gen multispecific therapeutic approaches. The co-located Peptides and Oligonucleotides programmes will focus on the discovery and innovative chemistry approaches for peptides and oligos, as well as their therapeutic development and optimization. Through the Sustainability in Tides & Biologics tracks, key opinion leaders will discuss progress towards sustainable supply chain development and commercialization of biologics. The Immunotherapy & Immuno-Oncology tracks will cover the discovery and development of cell and gene therapies, antibody-based treatments, combination therapies, and the microbiome-gut immune axis. The Vaccines tracks will explore various platforms for developing innovative vaccines, including the clinical development of mRNA vaccines. The agenda will feature C-level panel discussions, workshops, roundtables, and case study presentations, addressing market challenges and novel strategies, from enhancing the therapeutic potential of ADC drugs to optimizing upstream and downstream development.

Companies Represented Include

Introducing the Start-Up Zone

NextGen Biomed 2025 welcomes start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions. This introductory offer presents a unique opportunity to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals.

If you’re a start-up operating in the biologics, peptides, oligonucleotides, vaccine, or immunotherapy industries, apply now to secure your place in our Start-up Zone! We offer two options starting from £1,500 (+VAT) for how to get involved based on the size of your organization. For further information about our start up offer options please submit the application form below or contact Faye Moffatt at f.moffatt@oxfordglobal.com today.

Criteria:

To qualify for this offer, your company must be:

 

  • Therapeutic Start-Up, Emerging Technology OR Service Start-Up
  • Operating No More Than 5 Years
  • 0 – 30 employees
  • Pre-Series A Funding

 

Successful applications receive:

 

  • 1 Full Conference Pass
  • 10-Minute Presentation Opportunity
  • 1x1m Space in Start-Up Zone
  • Logo Featured on Event Website & App as a Participating Start-Up
  • Ability to Arrange Peer to Peer Meetings via the Congress App

Biotech Innovation & Collaboration

Inspiring Tomorrow’s Breakthroughs: Unleashing Innovation & Collaboration in NextGen Biomed Research & Development

Join engaging presentations featured in our innovation and collaboration track running across the full event, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprised of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biologics discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers
  • Discovering new investment opportunities with pharma
  • Learning about the latest industry trends & challenges
  • Keeping updated with new innovations and technology solutions
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

NextGen Biomed 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Fernando Albericio
Professor,
University of KwaZulu-Natal
Joël Richard
Chief Development Officer,
Enterome
Kelly Loyet
Distinguished Scientist,
Genentech
Livija Deban
Chief Scientific Officer,
Prokarium
Maja Firczuk
Protein Expression Technologies Team Leader,
GSK
Marta Amaral
Group Head High Throughput Protein Engineering in Large Molecules Research,
Sanofi
Martina Ochs
Project Leader,
CEPI
Reeta Daswani
Senior Scientist,
Sixfold
Rick Hibbert
Vice President & Head of CMC Science & Technologies,
Genmab
Shahram Lavasani
Chief Executive Officer,
ImmuneBiotech AB
Sudhir Agrawal
President & Founder,
ARNAY Sciences
Tristan Vaughan
Vice President Protein Engineering,
Immunocore
Aaron John Balana
Scientist III,
Genentech
Alain Wagner
Director,
Strasbourg University
Alastair Lawson
Vice President and Immunology Fellow,
UCB
Alessandra Tolomelli
Associate Professor,
University of Bologna
Alessandro Gori
Group leader,
National Research Council of Italy
Alexey Rak
Head of Bio Structure and Biophysics,
Sanofi
Álvaro Enríquez García
Medicinal chemist,
Eli Lilly
Amy Li
Director, Drug Discovery,
T-Therapeutics Ltd
Andrew Slee
Chief Operating Officer,
Protagenic Therapeutics
Andrew Jamieson
Professor,
University of Glasgow
Andrew Buchanan
Scientist,
AstraZeneca
Aneesh Karatt-Vellatt
CoFounder & CSO,
Maxion therapeutics
Anna Hine
Professor of Protein Engineering,
Aston University
Anna Maria Papini
Full Professor and Group leader of PeptLab,
University of Florence (Italy)
Antoine Leger
Development manager,
Affilogic
Aurelie Lacroix
Senior scientist,
Sixfold Bioscience
Baldur Sveinbjørnsson
Chief Scientific Officer,
Lytix Biopharma
Benjamin Lindner
Data Scientist,
Boehringer Ingelheim RCV GmbH & Co KG
Berit Olsen Krogh
Senior Research Fellow,
Lundbeck
Bryce Nelson
Head Protein and Antibody Engineering,
Orion
Chris Hart
CEO,
Creyon Bio
Christopher Scott
Professor,
Queen's University Belfast
Christopher Coxon
Senior Lecturer, Medicinal Chemistry,
THE UNIVERSITY OF EDINBURGH
Chun Kong Mak
Oligonucleotides Analytical Scientist,
Synthon
Dan Swerdlow
Senior Director,
GSK
Dan Hardy
CEO,
Microsol
Daniel Larocque
Innovation Leader,
Sanofi Vaccines
Daniel Sejer Pedersen
Specialist,
Novo Nordisk A/S
Darko Skegro
Associate Director,
Novartis
David Craik
Professor,
The University of Queensland
David Evans
Chief Scientific Officer,
Sirnaomics
David Brockwell
Professor,
University of Leeds
David Wraith
Professor of Immunology, Director of the Institute of Immunology and Immunotherapy,
University of Birmingham
Denise Steckel
Head of Clinical Collaborations Development,
Genentech
Ed Tate
Professor,
Imperial College London
Eef Dirksen
Group Leader,
Byondis B.V.
Emma Grant
Senior Analytical Development Scientist,
Immunocore
Emma Stanley
Director, Program Lead - Head of Antibody Discovery,
Mestag Therapeutics
Erik Vernet
VP - Scientific Data Registration,
Novo Nordisk
Fazel Shabanpoor
Lab Head Peptide And Oligonucleotide Therapeutics,
The Florey Institute of Neuroscience and Mental Health
Felix Schumacher
Program Leader Targeted Therapeutics,
Hoffmann La Roche Ltd
Francisca Wollerton
Senior Director of Protein Engineering and Novel Modalities,
AstraZeneca
Georgios Skretas
Director, Institute for Bioinnovation,
Biomedical Sciences Research Center "Alexander Fleming"
Hans Melo
Chief Executive Officer,
Menten Biotechnology Labs
Helen Bright
Chief Scientific Officer,
Centauri Therapeutics
Henry Maun
Associate Director,
Genentech
Hester Van Zeeburg
PM immunomonitoring,
Mendus AB
Ian Hamley
Professor of Physical Chemistry,
University of Reading
Ijeoma Uchegbu
Professor of Pharmaceutical Nanoscience,
University College London
Ilaria Poledri
Co-Founder,
ExCulture
Immanuel Lerner
Chief Executive Officer,
Pepticom
Isabelle Sermadiras
Associate Principal Scientist,
AstraZeneca
Janos Tibor Kodra
Principal Scientist,
Novo Nordisk
Jean Ge
Patent Attorney,
Wolf Greenfield
Jenny Fitting
Head of AAV and Protein Science,
Bayer
Jill Walker
Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics,
AstraZeneca
Jim Weterings
Vice President R&D USA,
Sirnaomics
John de Kruif
Executive Vice President & Chief Technology Officer,
Merus NV
John Maher
Chief Scientific Officer,
Leucid Bio
Jörg Wischhusen
Professor,
University Hospital Würzburg
Jutta Eichler
Professor,
University of Erlangen-Nurnberg
Karen Silence
Head Preclinical Product Development,
Argenx BVBA
Kevin Fitzgerald
Chief Scientific Officer,
Epsilogen
Kirsty Crame
Vice President Clinical Strategy & Development,
Medigene AG
Knud Jørgen Jensen
Professor,
Copenhagen University
Komal Kedia
Associate Principal Scientist,
Merck US
Kuda Muchandibaya
Lecturer for Supply Chain Management & Logistics,
Rhine-Waal University of Applied Sciences
Laura Starkie
Director,
UCB
Laurens Lindenburg
Principal Scientist,
Genmab
Leonardo De Maria
Principal Scientist,
AstraZeneca
Louis Diorazio
Senior Principal Scientist,
AstraZeneca
Lucas Bethge
VP, Group Leader Oligonucleotide Chemistry,
Silence Therapeutics
Luis Gómez-Morales
Scientific Project Manager,
Pepkon
Marc Vendrell
Professor of Translational Chemistry,
University of Edinburgh
Maria Fawaz
Associate Principal Scientist,
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.
Marie McAvoy
Chief Scientific Officer,
Nanosyrinx
Marina Fedorova
Scientific Investigator,
GSK
Matthew Burrell
Associate Director,
AstraZeneca
Mattias Malm
Senior Scientist,
Ferring Pharmaceuticals
Michael Dyson
Vice President,
Ichnos SA
Michael Delaney
Principal Scientist,
NovoNordisk
Michal Shoshan
CEO and Founder,
metaLead Therapeutics AG
Michelle Wantoch
Senior Scientist,
F-star Therapeutics Inc
Mikhail Kuravskiy
Principal Scientist,
UCB
Morten Lindow
RNAHub Founder & Mission Lead,
Roche
Nadim Akhtar
Senior Principal Scientist, New Modalities,
AstraZeneca
Norbert Furtmann
Head of AI Innovation - NANOBODY® Platform,
Sanofi
Obinna Ubah
Principal Scientist,
Elasmogen Limited
Owen Vickery
Computational Biologics Design,
AstraZeneca
Paul Wassmann
Senior Principal Scientist,
Novartis AG
Paul Reid
CSO,
Celtic Biotech
Pawel Stocki
Vice President R&D,
Ossianix
Pete Gough
Chief Scientific Officer,
Nimble Therapeutics
Prasun Chakraborty
Chief Executive Officer and Founder,
Genevation LTD
Rajika Perera
Chief Executive Officer,
Poseidon LLC
Rita Martello
Scientific Director, NBE DMPK Lead,
Dewpoint Therapeutics
Sandra Tremmel
Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,
F. Hoffmann-La Roche Ltd
Sandrien Janssens
CMC Director,
Mosanna Therapeutics
Sarah Stuart
HTC Team Leader,
GSK
Sarah Hindson
Senior Scientist,
GSK
Saul Martinez Montero
Senior Director, RNA Therapeutics,
Dyne Therapeutics
Simon Krah
Associate Director,
Merck Healthcare KgaA
Simon Plyte
Chief Scientific Officer,
Biomunex Pharmaceuticals
Simon Hufton
Section Head Molecular Immunology, Division of Biotherapeutics,
MHRA
Sonia Macia
Chief Medical Officer,
Aromics Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Sritama Bose
Head of Chemistry Research and Innovation,
Nucleic Acid Therapy Accelerator MRC
Stefan Zielonka
Director and Head of Antibody Discovery and Protein Engineering,
Merck Healthcare KGaA & Technische Universität Darmstadt
Stephen Miller
Principal Scientist,
Genentech
Steve Hood
Senior Director, Oligonucleotide ADME Strategy, DMPK,
GSK
Steven Schmitt
Co-Founder & CEO,
Myria Biosciences
Sue Charlton
Head of Clinical Evaluation,
UKHSA
Talip Ucar
Senior Director - AI Research,
AstraZeneca
Tatyana Ponomaryov
Principal scientist,
Plasticell
Thomas Kraft
Principal Scientist,
Roche
Tim Hickling
Investigative Safety and Immunosafety Chapter Lead,
Hoffmann La Roche Ltd
Tomáš Hanke
Professor,
University of Oxford
Vincent Dewar
Head of Immunoassay,
GSK
Vincenzo de Filippis
Associate Professor Biochemistry,
University of Padova
Vladimir Gligorijevic
Senior Director of AI/ML,
Genentech
Walter Cabri
Full Professor of Organic Chemistry,
University of Bologna
Wen Chang
Associate Vice President Discovery and Early Development,
AcuraStem
Will Nesbit
Director - Process Chemistry, CMC,
Bicycle Therapeutics
Yi Yang
Principal Scientist,
Ferring Pharmaceuticals A/S
Zahra Rattray
Senior Lecturer,
University of Strathclyde

Interested in Sponsoring?

Our extensive and engaged community extends across large, mid-size and emerging companies within the pharma and biotech space, with a dedicated audience spanning a range of specialisms. Whether you have content to share, are looking for ways to enhance your brand visibility or would like to increase engagement with prospective customers, Oxford Global can offer valuable access to your target demographic through our range of event & content services.

Latest Resources

Absci to Collaborate with the Memorial Sloan Kettering Cancer Center to Develop Biologics using AI

The two organisations will work side by side on up to six programmes which will develop new cancer drug candidates using AI.

RSC 'Emerging Technologies' Award Goes to Solid Phase Peptide Synthesis Group

The novel peptide synthesis protocol allows the synthesis of multiple peptide fragments on a single bead.

FDA Fast Track ADC for Patients with Triple Negative Breast Cancer

The fast track designation means that the clinical development and regulatory milestones of the drug candidate are likely to progress much faster.

GSK Buys CureVac's mRNA Vaccine Business Providing Welcome Cash Injection

CureVac will continue to build its R&D pipeline while allowing GSK to develop and commercialise a handful of its prophylactic mRNA vaccines.

Unlocking the Future of Immune Cancer Therapy

A concise report featuring insights from the prominent though leaders of Immuno 2024.

2002 Nobel Prize for Chemistry: Kurt Wüthrich, Using NMR to Determine the 3D Structure of Proteins

Kurt Wüthrich, joint winner of the 2002 Nobel Prize for Chemistry, contributed to the use of NMR to discover the 3D structure of proteins using sequential assignment and mathematical techniques.

Plan Your Visit

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2025, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of NextGen Biomed 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch